title: Plasmodium vivax: comparison of the immune responses between oral and parenteral immunization of rPv54 in BALB/c mice.
abstract: The merozoite surface protein-1 (MSP-1) from Plasmodium vivax was evaluated as an oral vaccine candidate by cloning and expressing the interspecies conserved block 10 (ICB10) of the MSP-1 from a Korean isolate in Escherichia coli. The expressed fusion protein contained ICB10 and a maltose-binding protein (MBP), rPv54, has a molecular weight of approximately 54 kDa as determined by SDS-PAGE analysis. IgG against rPv54 was successfully produced in BALB/c mice by oral immunization and sustained for more than 4 months. IgG2b was dominantly produced in both oral and parenteral immunizations. The rPv54 increased the frequency of NK, NKT, CD4+ T, CD8+ T, and B cells in both immunizations. IL-5 and TNF-alpha were increased in both significantly. In conclusion, rPv54 might be a valuable potential vaccine candidate for the oral and parenteral immunization against vivax malaria.
authors.affiliation: Division of Malaria and Parasitic Diseases, National Institute of Health, Centers for Disease Control and Prevention, Seoul 122-701, Republic of Korea.
authors.forename: Myoung-Hee
authors.initials: MH
authors.lastname: Kwon
authors.forename: Hyung-Hwan
authors.initials: HH
authors.lastname: Kim
authors.forename: Ho-Sa
authors.initials: HS
authors.lastname: Lee
authors.forename: Tong-Soo
authors.initials: TS
authors.lastname: Kim
authors.forename: Chang-Mi
authors.initials: CM
authors.lastname: Oh
authors.forename: Yong-Joo
authors.initials: YJ
authors.lastname: Ahn
authors.forename: Seo-Kyong
authors.initials: SK
authors.lastname: Hwang
authors.forename: Youngjoo
authors.initials: Y
authors.lastname: Sohn
authors.forename: Hyuck
authors.initials: H
authors.lastname: Kim
authors.forename: Hyeong-Woo
authors.initials: HW
authors.lastname: Lee
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000913:Antibodies, Protozoan / Q000096:biosynthesis; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000096:biosynthesis; D007263:Infusions, Parenteral; D015848:Interleukin-5 / Q000378:metabolism; D016780:Malaria, Vivax / Q000517:prevention & control; D058619:Maltose-Binding Proteins; D020066:Merozoite Surface Protein 1 / Q000737:chemistry / Q000235:genetics / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D033902:Periplasmic Binding Proteins / Q000737:chemistry / Q000235:genetics / Q000276:immunology*; D010966:Plasmodium vivax / Q000276:immunology*; D016052:Protozoan Vaccines / Q000008:administration & dosage* / Q000276:immunology; D011993:Recombinant Fusion Proteins / Q000737:chemistry / Q000235:genetics / Q000276:immunology*; D013154:Spleen / Q000166:cytology / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology
chemical_list: D000913:Antibodies, Protozoan; D007074:Immunoglobulin G; D015848:Interleukin-5; D058619:Maltose-Binding Proteins; D020066:Merozoite Surface Protein 1; D033902:Periplasmic Binding Proteins; D016052:Protozoan Vaccines; D011993:Recombinant Fusion Proteins; D014409:Tumor Necrosis Factor-alpha; D014614:Vaccines, Synthetic